WilliamDamskyMD

Dermatopathology

Assistant Professor of Dermatology and Pathology

Dr. Damsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
428 Columbus Ave
New Haven, CT 06519
Phone+1 203-503-3000

Fax+1 203-785-7637

Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare Start of enrollment: 2019 Apr 11
Completed
Phase 1
Janus Kinase Inhibition in Sarcoidosis Start of enrollment: 2023 Jun 01
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Janus Kinase Inhibition in Granuloma Annulare Start of enrollment: 2023 Oct 27
Active, not recruiting
Phase 2
Roles: Sponsor-Investigator, Principal Investigator, Contact

PubMed

Enhanced Intratumoral Delivery of Immunomodulator Monophosphoryl Lipid A through Hyperbranched Polyglycerol-Coated Biodegradable Nanoparticles.
Jungsoo Chang, Kwangsoo Shin, Julia M Lewis, Hee Won Suh, Joohyung Lee
The Journal of Investigative Dermatology. 2025-03-01
Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma.
Meaghan K McGeary, William Damsky, Andrew J Daniels, Sabine M Lang, Qingji Xu
Cancer Immunology Research. 2025-02-03
Grover disease shows Type 2 immune activation and improves with dupilumab.
Michael J Murphy, Muhammad H Junejo, Okeroghene Rufin, Jeffrey M Cohen, Caroline A Nelson
The British Journal of Dermatology. 2025-01-07

Lectures

JAK Inhibitors: A New Frontier in Dermatology
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/1/2019

Novel LDTs Advance Dermatological DiagnosticsFebruary 14th, 2025
TNF or JAK: Which Target Is Key to Success in Tough-to-Treat Skin Disease?November 11th, 2021
Dramatic Responses in Cutaneous Sarcoidosis with JAK InhibitorNovember 7th, 2021
Join now to see all